StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Cartesian Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -10518.6%. For fiscal 2025 it was -5127.1%, against -112.8% the year before. The highest annual figure on record is 13.1% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-5127.1%−5014.3
FY2024Dec 31, 2024-112.8%+219.5
FY2023Dec 31, 2023-332.3%−345.4
FY2022Dec 31, 202213.1%+18.5
FY2021Dec 31, 2021-5.4%+337.0
FY2020Dec 31, 2020-342.4%+443.3
FY2019Dec 31, 2019-785.6%+6415.1
FY2018Dec 31, 2018-7200.7%+23612.9
FY2017Dec 31, 2017-30813.5%−30384.6
FY2016Dec 31, 2016-428.9%−8.0
FY2015Dec 31, 2015-421.0%+85.6
FY2014Dec 31, 2014-506.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-33973.1%−31983.2
Q4 FY2025Dec 31, 2025-8304.0%−3762.7
Q3 FY2025Sep 30, 2025-4660.6%−4701.8
Q2 FY2025Jun 30, 2025-7319.1%−7090.6
Q1 FY2025Mar 31, 2025-1989.9%−1550.4
Q3 FY2024Sep 30, 2024-4541.3%−4341.9
Q2 FY2024Jun 30, 202441.1%+396.2
Q1 FY2024Mar 31, 2024-228.6%+81.0
Q4 FY2023Dec 31, 2023-439.5%−388.9
Q3 FY2023Sep 30, 2023-199.4%−191.7
Q2 FY2023Jun 30, 2023-355.1%−390.4
Q1 FY2023Mar 31, 2023-309.5%−341.2
Q4 FY2022Dec 31, 2022-50.6%−64.2
Q3 FY2022Sep 30, 2022-7.7%+0.3
Q2 FY2022Jun 30, 202235.3%+33.0
Q1 FY2022Mar 31, 202231.7%+96.5
Q4 FY2021Dec 31, 202113.6%+79.7
Q3 FY2021Sep 30, 2021-8.1%+287.5
Q2 FY2021Jun 30, 20212.3%+191.2
Q1 FY2021Mar 31, 2021-64.8%+124819.8
Q4 FY2020Dec 31, 2020-66.1%+118493.9
Q3 FY2020Sep 30, 2020-295.6%+1310.0
Q4 FY2019Dec 31, 2019-188.9%+113205.2
Q2 FY2019Jun 30, 2019-124884.6%−73573.5
Q1 FY2019Mar 31, 2019-118560.0%−57517.7
Q4 FY2018Dec 31, 2018-1605.6%+9184.1
Q4 FY2017Dec 31, 2017-113394.1%−112921.1
Q3 FY2017Sep 30, 2017-51311.1%−50598.5
Q2 FY2017Jun 30, 2017-61042.3%–
Q1 FY2017Mar 31, 2017-10789.8%–
Q4 FY2016Dec 31, 2016-473.0%–
Q3 FY2016Sep 30, 2016-712.6%–

More Cartesian Therapeutics figures

See a number that looks wrong?